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ABSTRACT
Exportin-1 (CRM1/XPO1) is a crucial nuclear export protein that transports a 
wide variety of proteins from the nucleus to the cytoplasm. These cargo proteins 
include tumor suppressors and growth-regulatory factors and as such XPO1 is 
considered a potential anti-cancer target. From this perspective, inhibition of the 
XPO1-mediated nuclear export by selective inhibitor of nuclear export (SINE) 
compounds has shown broad-spectrum anti-cancer activity. Furthermore, the clinical 
candidate SINE, selinexor, is currently in multiple phase I/II/IIb trials for treatment 
of cancer. Resistance against selinexor has not yet been observed in the clinic, but in 
vitro selection of resistance did not reveal any mutations in the target protein, XPO1. 
However, introduction of a homozygous mutation at the drug’s target site, the cysteine 
528 residue inside the XPO1 cargo-binding pocket, by genetic engineering, confers 
resistance to selinexor. Here we investigated whether this resistance to selinexor is 
recessive or dominant. For this purpose we have engineered multiple leukemia cell 
lines containing heterozygous or homozygous C528S substitutions using CRISPR/
Cas9-mediated genome editing. Our findings show that heterozygous mutation confers 
similar resistance against selinexor as homozygous substitution, demonstrating that 
SINE resistance can be obtained by a single and dominant mutation of the cysteine528 
residue in XPO1.
INTRODUCTION
Human exportin 1 (XPO1), also known as 
chromosome region maintenance 1 protein (CRM1), is a 
ubiquitously expressed member of the importin-β family 
of nucleocytoplasmic transport proteins (also known as 
karyopherins). XPO1 mediates the export of many different 
cargo proteins from the nucleus to the cytoplasm, including 
tumor suppressive or growth regulatory related proteins such 
as nucleophosmin, p53, p21, pRb, BRCA1, APC and FOXO 
family proteins, but also viral proteins, such as HIV-1 Rev, 
are transported by XPO1 [1]. XPO1 has been considered a 
potential molecular target for therapeutic intervention for 
decades and in recent years, its overexpression has been 
associated with malignancy [2-6] and XPO1 has been 
considered a potential molecular target for therapeutic 
intervention for decades. Yet, only recently the first clinical 
validation of pharmacological inhibition of XPO1 came with 
the discovery of the selective inhibitor of nuclear export 
(SINE) compounds. SINE are orally bioavailable, optimized 
N-azolylacrylate derivative small-molecule inhibitors of the 
XPO1-mediated nuclear protein export [7-10]. They bind 
into the hydrophobic cargo-binding groove of XPO1 and 
covalently modify the cysteine528 residue through a Michael 
type addition, thereby preventing the interaction of cargo with 
XPO1. Currently, the leading candidate of the SINE, selinexor 
(KPT-330), is under investigation in multiple stage I/II/IIb 
clinical trials. Natural or acquired resistance to selinexor has 
not been observed in the clinic, but in an attempt to select for 
resistance against these compounds in vitro, Crochiere and 
colleagues treated HT-1080 cells with gradually increasing 
concentrations of the drug [11]. Resistance was reached 
only after an extensive period of 10 months of continuous 
exposure. Resistant cells displayed an altered expression 
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pattern in a number of key signaling pathways, including 
upregulation of anti-apoptotic and downregulation of 
pro-apoptotic genes. These cells were also >100 fold less 
sensitive to SINEs and even though they showed nuclear 
accumulation of XPO1 cargo-proteins in resistant cells after 
treatment as compared to the parental cells, they did not 
incorporate any mutations in the cargo-binding pocket of 
XPO1. This hydrophobic cargo-binding cleft of XPO1, and 
especially the cysteine528 residue located in this cleft, is highly 
conserved amongst higher eukaryotes. However, recently, in 
an effort to validate the SINE-XPO1 drug-target interaction, 
we were able to successfully engineer the genome of Jurkat 
leukemic T-cells to substitute cysteine528, the anchor point of 
selinexor inside the cargo-binding pocket of XPO1, with a 
serine. These homozygous genome-edited XPO1C528S Jurkat 
cells were viable and showed a >250 fold resistance to SINE 
compounds, demonstrating that the anti-cancer activity of 
SINE compounds effectively results from XPO1 inhibition 
[12]. In this current study, we investigate the effect of 
heterozygous substitutions of the XPO1 cysteine 528 residue 
on SINE activity in cellulo.
RESULTS
Generation of XPO1C528S knock-in mutants by 
CRISPR/Cas9 genome editing
In order to obtain cell lines carrying a cysteine 
to serine substitution at position 528 inside the XPO1 
hydrophobic cargo-binding pocket, we applied CRISPR/
Cas9 genome editing to alter the corresponding TGT 
DNA codon to TCA (Figure 1a). HL-60, Jurkat and 
K-562 leukemia cells were co-transfected with plasmids 
expressing Cas9-NLS and an XPO1 targeting single 
guide RNA together with a 135 bases single-stranded 
oligodeoxynucleotide repair donor template containing 
the TGT to TCA mutation in addition to 3 silent mutations 
(Figure 1a). To enrich for cells that underwent homology 
directed repair with the 135 base oligo, transfected cells 
were treated with a relatively low dose of KPT-185 
(Figure 1b) for 3 consecutive days. Only few cells 
survived (<10%), indicating a low efficiency of homology 
directed repair. The amount of surviving cells was highly 
dependent on transfection efficiency and cell-type, as more 
cells clearly survived in the easy to transfect K-562 and 
HL-60 cell lines (data not shown). Following transfection, 
single cells were distributed into 96-well plates to obtain 
single cell derived colonies. From these colonies genomic 
DNA was extracted and exon 15 of the XPO1 gene was 
sequenced by Sanger sequencing. The majority of the 
clones integrated the desired missense mutation at only 
one of the XPO1 alleles, while the other allele contained 
either the wild-type sequence, the silent mutations only, 
but not the desired missense mutation, or an insertion or 
deletion caused by non-homologous end-joining (NHEJ) 
(classified as hemizygous) (Figure 1c, Table 1). The 
remaining clones integrated the TGT to TCA mutation in 
both alleles. Two of the K-562 colonies only contained 
the wild-type sequence, suggesting that they tolerated the 
initial low dose selection with KPT-185. All sequences 
containing the desired missense TCA mutation also 
contained the three silent mutations, effectively ruling out 
spontaneous generation of resistance mutations during 
drug selective pressure.
To confirm that these homozygous and heterozygous 
clones express mutant XPO1C528S protein, wild-type XPO1 
was extracted out of the cells with a biotinylated SINE 
compound, KPT-9058 (Figure 1d). KPT-9058 carries 
the typical acrylate-derived warhead required to bind 
cysteine528 of wild-type XPO1 [9] and it does not bind 
XPO1 protein containing the Cys528Ser mutation [12]. 
Wild-type, heterozygous and homozygous mutant cells 
were treated with KPT-9058 for 2 hours and KPT-9058 
was then extracted from the cell lysate by streptavidin 
affinity purification. The co-precipitated XPO1 protein was 
detected by western blot analysis (Figure 1e). As expected, 
XPO1 protein was pulled down from wild-type cells, 
while it was impossible to extract XPO1 protein from the 
homozygous XPO1C528S mutant cells. Quantification of the 
pulled down protein from heterozygous XPO1C528S mutants 
showed that the amount of pulled down XPO1 protein 
was about half of that pulled down from wild-type cells 
(Figure 1f), confirming that half of the expressed XPO1 
in the heterozygous mutants consists of wild-type protein 
while the other half consists of mutant XPO1C528S protein.
The mutant cells appeared to grow slightly slower. 
To investigate this phenotype further, the cell proliferation 
of wild-type, heterozygous and homozygous mutants was 
analyzed over a period of 3-4 days (Figure 1g). A slightly 
slower growth rate in most of the mutant cells, and 
especially in the homozygous mutants, became apparent. 
More specifically, the growth rate was significantly lower 
in all Jurkat and HL-60 mutant cell lines when compared 
to the parental wild-type cell-line (p<0.0001). However, 
the growth rate of the heterozygous K-562 mutant cell 
line was not significantly different when compared to the 
parental wild-type (p=0.0968), but the homozygous K-562 
mutant clearly did grow slower (p<0.0001). Finally, no 
significant differences in cell size between the hetero- and 
homozygous mutants and their respective parental wild-
type cell line were observed (Figure 1h, p-values between 
0.4 and 0.9).
Heterozygous substitution of cysteine528 in XPO1 
confers resistance to XPO1 inhibitors
To investigate whether resistance to selinexor (KPT-
330, Figure 1b) is recessive or dominant for the cysteine528 
mutation, hetero- and homozygous mutants, together with 
wild-type cells, were treated with selinexor. A remarkable 
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Figure 1: generation of heterozygous and homozygous XPO1C528S cell lines A. Schematic representation of the setup for 
CRISPR/Cas9 genome editing of XPO1. The numbered green boxes represent exons of XPO1. The wild-type sequence around cysteine528 
located in exon 15 is enlarged. The sgRNA sequence is highlighted, its corresponding Cas9 cutting site is denoted by a red arrowhead 
and the PAM site is underlined. The donor oligo sequence used for homology directed repair (HDR) is shown below. The Cys528Ser 
missense mutation is highlighted in bold and the 3 additional silent mutations are highlighted in small red letters. B. Chemical structure 
of the selective inhibitors of nuclear export KPT-185 and KPT-330 (Selinexor). C. Sanger sequencing chromatograms of the generated 
heterozygous and homozygous XPO1C528S cell lines. The desired nucleotide mutations are highlighted in bold, while silent mutations are 
shown in red. The amino acid residue located at position 528 is shown in the blue boxes. D. The chemical structure of the biotinylated 
selective inhibitor of nuclear export KPT-9058. The biotin moiety is highlighted in light grey and the active warhead, which binds to XPO1 
is shown in black E. Pull down of XPO1 with KPT-9058. KPT-9058 bound to XPO1 was extracted by streptavidin affinity from Jurkat 
wild-type or mutant cells. β-tubulin (loading control) and XPO1 were visualized by immunoblotting of the extract (top) and the total lysate 
(below) after 2h treatment with DMSO or 1 µM KPT-9058. (Continued )
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reduction in cell viability of wild-type K-562, HL-60 and 
Jurkat cells was observed at nanomolar concentrations, 
while all the heterozygous and homozygous mutant 
cell lines were resistant to selinexor up to micromolar 
concentrations (Figure 2a; Table 2). Interestingly, there 
was no marked difference in resistance profile to selinexor 
between the heterozygous and homozygous mutants, 
demonstrating that the obtained genetic drug resistance to 
selinexor is dominant.
To confirm that a heterozygous Cys to Ser mutation 
in XPO1 is sufficient for selinexor resistance, we further 
examined the effect of selinexor on the XPO1-mediated 
nuclear export in heterozygous mutant cells. For this 
purpose, Jurkat cells were stained for endogenous 
RanBP1, which is a XPO1 cargo protein that is actively 
exported from the nucleus by XPO1 and localizes mainly 
to the cytoplasm in both wild-type and mutant cells 
(Figure 2b panel a). Upon treatment of wild-type cells with 
Figure 1: (Continued ) Generation of heterozygous and homozygous XPO1C528S cell lines. F. Quantification of the XPO1 pull 
down with KPT-9058. The signal intensity (area under the curve) of the extracted XPO1 was quantified, divided by the signal intensity of 
β-tubulin and then compared to the wild-type. Bars represent means relative to the extraction from wild-type cells and error bars indicate 
standard deviation (N=2 repeated measurements of the same samples). The amount of XPO1 extracted from wild-type cells with DMSO is 
also shown for comparison. G. Quantification of cellular growth rates from parental wild-type or heterozygous and homozygous XPO1C528S 
mutant cell lines. Cellular growth was analyzed over a period of 3-4 days and normalized to day 0. Data points represent means and error 
bars indicate the standard deviation (N=2, N=3 for Jurkat). Exponential growth curves were obtained by fitting with GraphPad Prism. 
H. Quantification of the cell diameter of wild-type and heterozygous or homozygous XPO1C528S cell lines. Cell diameters were analyzed 
with a LUNA automated cell counter. Bars represent means and error bars indicate standard deviation (N=3).
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up to 3 μM selinexor for 3 hours, RanBP1 accumulated in 
the nucleus as a result from the inhibition of the XPO1-
mediated nuclear export by the drug. In heterozygous 
mutant XPO1C528S expressing cells, RanBP1 subcellular 
localization was unaffected upon selinexor treatment, 
demonstrating that a single heterozygous substitution of 
the XPO1 cysteine528 residue is sufficient for resistance 
against the SINE compounds (Figure 2b panel b). For 
each condition a minimal number of 200 cells were 
analyzed for the ratio of nuclear over cytoplasmic RanBP1 
staining (Figure 2c). Remarkably, heterozygous mutants 
again showed a similar resistance profile as homozygous 
mutants. All in all, these findings further strengthen the 
conclusion that heterozygous mutation of the cysteine528 
residue is sufficient for drug resistance.
DISCUSSION
Exportin-1 (XPO1, CRM1) is a crucial protein 
involved in the nuclear export of many cellular proteins 
[13], including various tumor suppressive and growth 
regulatory proteins. Overexpression of XPO1 has been 
associated with various forms of cancer [2-6] and the 
inhibition of the XPO1-mediated nuclear export by small 
molecules has been shown to induce apoptosis and abolish 
cancer growth in in vitro as well as in vivo models of 
cancer [8, 9, 14]. The orally bio-available small-molecule 
XPO1 inhibitors called selective inhibitor of nuclear 
export (SINE) compounds, have proven anti-cancer 
activity in hematological and solid cancers, while sparing 
normal cells and showing limited off-target complications 
[7, 8]. Especially selinexor, the clinical candidate of this 
class of compounds, is showing promising results as single 
agent in patients with heavily pre-treated and relapsed 
hematological or solid cancer in multiple stage I/II/IIb 
clinical trials [15].
The drug has been shown to specifically and 
selectively interact with the cysteine528 residue located 
in the hydrophobic cargo-binding pocket of XPO1 [12]. 
Although this residue is conserved in higher eukaryotes, 
we generated multiple heterozygous and homozygous 
mutant leukemia cell lines containing a serine residue 
instead of the cysteine by using CRISPR/Cas9 knock-in 
genome editing. We demonstrated that the cys528 to ser 
substitution conferred cells with >100-fold resistance 
to selinexor. Using the biotinylated SINE compound 
KPT-9058 we showed that in heterozygous mutant cells, 
wild-type and mutant XPO1 are expressed in a 50/50 
distribution. The XPO1C528S protein expressed from the 
mutant allele in these heterozygous mutants is sufficient to 
elicit complete resistance to selinexor, demonstrating the 
dominant nature of this resistance mutation. Furthermore, 
this dominant resistance also demonstrates that 50% 
of the total XPO1 protein pool is sufficient for cellular 
homeostasis of the cell. However, the cysteine substitution 
appears to affect the cell proliferation slightly, which 
might be explained by an altered affinity of mutant 
XPO1C528S to a subset of cargo-proteins, which in turn 
might alter the nuclear-cytoplasmic distribution of these 
XPO1 cargo proteins.
Little is known on possible resistance mechanisms 
to selinexor in vivo. Several studies focused on patient 
samples have suggested that recurrent mutation of residue 
E571 located in the NES binding groove of XPO1 might 
have prognostic or therapeutic value for different types 
of cancer [16-20]. However, this mutation does not 
alter selinexor sensitivity in primary mediastinal B-cell 
lymphoma [18]. Furthermore, a cryptic fusion of XPO1 
with MLLT10 has been reported in T-ALL [21], but the 
effect of this translocation on selinexor activity remains 
to be investigated. Finally, the cysteine528 residue is 
highly conserved and mutation has not been observed 
in in vivo models. Additionally, selinexor is currently 
under investigation in many different clinical trials 
focused on its anticancer activity, but to our knowledge 
none of these trials have examined the appearance of 
cysteine528 mutations in the different treatment regimens. 
Nevertheless, here we have shown that heterozygous 
substitution of this single residue is sufficient to confer 
cells with resistance against selinexor. Interestingly, 
this mutation also resulted in decreased cellular growth 
rates, suggesting this mutation might reduce cancer cell 
fitness. However, further in vivo studies are needed to fully 
elucidate the possible effect of cysteine substitutions on 
cellular homeostasis, cancer cell fitness or tumor growth 
rate and selinexors anticancer activity.
To summarize, this study provides important 
predictive information of a possible resistance 
mechanism that could arise upon selinexor treatment. 
However, it remains to be seen whether a heterozygous 
Table 1: overview of the obtained mutant clones after CRISPR/Cas9 genome editing
XPO1 Cysteine528 substitution Total Clones
Cell line Leukemia Substitution Homozygous Heterozygous Hemizygous Wild-
type
HL-60 APML TGT528->TCA 21 (21.9%) 22 (22.9%) 53 (55.2%) 0 (0%) 96
Jurkat T-ALL TGT528->TCA 2 (12.5%) 10 (62.5%) 4 (25%) 0 (0%) 16
K-562 CML TGT528->TCA 24 (33.3%) 11 (15.3%) 35 (48.6%) 2 (2.8%) 72
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or homozygous mutation of the XPO1 cysteine528 can 
arise in the clinic. Overall our results demonstrate 
that heterozygous genomic mutation of cysteine528 in 
XPO1 is sufficient for the development of a resistance 
mechanism to selinexor and further highlight the 
applicability of CRISPR/Cas9 genome editing for 
recessive and dominant drug-target interaction and 
validation studies.
Figure 2: heterozygous substitution of cysteine528 in XPO1 by serine confers drug resistance. A. Viability assays of the different 
cell lines treated with increasing concentrations of KPT-330 (selinexor) are plotted. Cell viability is expressed on the Y-axis as a fraction of 
the total response of untreated (DMSO) cells. The X-axis represents the drug concentration in nanomolar on a log10 scale. Points represent the 
average and error bars indicate standard deviation (N=3 duplicates). B. Visualization of the XPO1-mediated nuclear export of the cargo protein 
RanBP1. RanBP1 was visualized (green) with a high content imaging system by immunostaining of Jurkat cells treated for 3 hours with DMSO 
or increasing concentrations of KPT-330. Cell nuclei were counterstained with DAPI (blue). Panel a - visualization of the RanBP1 localization 
after treatment with DMSO. Panel b - visualization of the RanBP1 localization after treatment with 3 µM KPT-330. C. Quantification of the 
nuclear/cytoplasmic distribution of the XPO1 cargo protein RanBP1 as visualized by immunostaining. The Y-axis represents the ratio of 
the average nuclear signal divided by the average cytoplasmic signal on a cell per cell basis. The X-axis represents the drug concentration 




HL-60, Jurkat and K-562 cells were obtained from 
ATCC. All cells were cultured in 75cm2 flasks at 37°C 
and 4,5% CO2. Cells were grown in complete RPMI 1640 
(Jurkat) or IMDM medium (HL-60, K-562) containing 
2 mM L-glutamine and supplemented with 10% fetal 
bovine serum and 20 µg/mL gentamicin. Cells were kept 
between 3 to 15 x 105 cells per mL.
CRISPR/Cas9 knock-in
HL-60, Jurkat, and K-562 cells were transfected 
using electroporation with a Neon Transfection system 
(Invitrogen, Life Technologies). Briefly, cells were collected 
by centrifugation at 400xg and resuspended in Resuspension 
Buffer R (Invitrogen, Life Technologies) according to the 
instructions. Purified and highly concentrated DNA plasmids 
expressing Cas9-NLS (0.5 µg), single guide RNA targeting 
XPO1 (0.5 µg) and the donor cys528ser oligonucleotide 
(1 µg) were added to the resuspended cells. Next the 
mixture, containing 200.000 cells, was electroporated with 
the following settings: 10 μL, 1350V, 10 ms and 3 pulses. 
Following electroporation, cells were immediately plated in 1 
mL of antibiotic free RPMI 1640 or IMDM Medium (Gibco, 
Life Technologies) containing 10% fetal bovine serum in 
a 24-well plate and cultured at 37°C in a CO2 incubator. 
After two days the medium was refreshed and KPT-185 
was added to a final concentration of 100 nM. Cells were 
then maintained and grown in the presence of the compound 
over a period of 1-3 weeks following standard cell culture 
guidelines. After this period, surviving cells were harvested 
and cultured further. When cultures were sufficiently grown, 
cells were plated at a density of 0.5 cells/well in 96-well 
plates in 20% FBS containing medium to obtain single cell 
derived colonies. Colonies were grown for 2-6 weeks and 
were regularly screened. Ultimately, colonies were harvested 
and the genomic DNA was extracted for Sanger sequencing.
DNA constructs
The optimized sgRNA construct targeting XPO1 near 
the cys528 coding region contains the following targeting 
sequence: 5’ GGATTATGTGAACAGAAAAG 3’-AGG 
(bold indicates the NGG protospacer adjacent motif). 
The oligonucleotide used for homologous recombination 
consisted of a 135 bases single stranded deoxynucleotide 
molecule containing two outer arms (50-80bp) homologous 
to the XPO1 genomic region flanking the codon for 
cysteine528 of XPO1 and was synthesized by Integrated 
DNA Technologies. The oligonucleotide contained three 
silent mutations near the PAM site and two point mutations 
at the cys528 coding triplet to provide the template for 





AGG-‘3 (bold indicates the cys528ser missense mutation, 
lowercase and underlined indicates additional silent).
DNA extraction and sequencing
When single cell derived colonies in 96-well plates 
were sufficiently grown, cells were washed and then 
lysed in Bradley lysis buffer at 56°C (10 mM Tris-HCl 
(pH 7.5), 10 mM EDTA, 0.5% SDS, 10 mM NaCl and 
1 μg/mL proteinase K). The genomic DNA was extracted 
from the lysate using ethanol-salt precipitation coupled 
to centrifugation. The target site, the DNA sequence 
around XPO1, was amplified by PCR with the following 
primers: fwd: 5’-TCTGCCTCTCCGTTGCTTTC, rv: 
5’-CCAATCATGTACCCCACAGCT. After PCR, 
the products were sequenced by Sanger Sequencing 
(Macrogen) using a forward and reverse primer 
(5’-TGTGTTGGGCAATAGGCTCC, 5’-GGCATTTTTG 
GGCTATTTTAATGAAA respectively).
XPO1 pull down with KPT-9058
For pull down of XPO1 out of cells using KPT-
9058, 5x106 Jurkat cells were plated in 1.5 mL of RPMI 
supplementend with 2 mM L-glutamine, 10% FBS and 
20 µg/mL gentamicin inside 6-well plates. After a few 
hours inside the incubator, 1.5 mL of RPMI containing 2 
µM of KPT-9058 was added to the cells (final concentration 
1 µM). Cells were incubated for 2 hours and then collected 
by centrifugation (400xg) and washed in ice-cold PBS. Cell 
pellets obtained after centrifugation (400xg) were lysed on 
ice in RIPA buffer supplemented with 1x HALT protease 
Table 2: overview of the EC50 values of selinexor obtained from the cell viability tests
Cell Line EC50 (nM)
XPO1WT/WT XPO1WT/C528S XPO1C528S/C528S
HL-60 125.8 ± 22.5 12,683 ± 3,006 12,364 ±6,360
Jurkat 53.15 ± 3.6 6,490 ± 2,582 16,987 ± 1,052
K-562 183.7 ± 26.2 55,360 ± 13,836 38,575 ± 5,048
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inhibitors (Thermo Scientific) and then cleared from debris 
by centrifugation at 20.000xg for 10 min at 4°C. Protein 
concentrations were measured using a colorimetric BSA 
protein assay (Pierce). A fraction of the cell lysis mixture 
was taken for quantification of β-tubulin and XPO1 total 
protein. The rest of the extracts were allowed to bind to 
Dynabeads MyOne Streptavidin T1 (Life Technologies) 
by rotating overnight at 4°C in order to capture KPT-9058. 
Following overnight incubation, the beads were washed 5 
times in modified RIPA buffer (50 mM Tris-HCl pH 7.8, 
150 mM NaCl, 1% NP-40 (IGEPAL CA-630), 0.1% sodium 
deoxycholate, 1 mM EDTA) and subsequently boiled for 
10 minutes in 0.5% SDS containing 1x sample buffer 
(Protein Simple) to elute captured proteins. Proteins were 
finally separated by size (12-230 kDa) and visualized on 
a Wes system (Protein Simple) with an anti-rabbit HRP 
conjugated antibody detecting the primary XPO1 (1/12500, 
NB100-79802) and β-Tubulin (1/3000, NB600-936) rabbit 
antibodies. Protein signals were visualized and quantified 
with the Compass software, v2.7.1 (Protein Simple).
Cell growth and size assays
Growth rates of mutant and wild-type cell lines were 
determined with the CyQuant Direct Cell Proliferation 
kit (ThermoFisher Scientific). Initially a standard curve 
was obtained to determine the relation of the fluorescent 
signal to the amount of cells present in the sample. For 
the experiment, 20.000 Jurkat cells or 10.000 K-562 and 
HL-60 cells were seeded in different 96-well plates on 
day 0 in complete RPMI or IMDM medium respectively. 
The cells were allowed to grow over a period of 3-4 days 
and the amount of cells was determined every 24 hours 
by measuring fluorescence of the CyQuant Direct Cell 
Proliferation reagent with a SaFire II microplate reader 
according to the manufacturer’s instructions. The obtained 
data points were compared to the previously obtained 
standard curves and cell numbers were normalized to day 
0. Growth curves were then obtained by fitting the data 
with an exponential growth curve in GraphPad Prism and 
statistical significance was determined. The experiment was 
performed in triplicate and repeated at least once. For the 
determination of average cell sizes, all cells were analyzed 
during 3 different passages with the LUNA automated 
cell counter (Logos Biosystems). Statistical significance 
between cell sizes was determined with ANOVA.
Cell viability assays
Cell viability assays were performed by plating 
10.000-20.000 cells in 96-well plates containing 
DMSO or a dilution of KPT-330. Cells were incubated 
for 72 hours at 37°C and 4.5% CO2. Cell viability 
was assessed with the CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay reagent (Promega) 
according to the manufacturer’s instructions. Absorbance 
of the samples was measured at 490 nm using a SaFire 
II microplate reader (Tecan). All assays were performed 
in duplicate and each experiment was repeated at least 
three times. The data was analyzed using a log-based 
4 parameter model in GraphPad Prism and the bottom 
value for the EC50 calculation was set by hand for the 
mutant K-562 cells.
High content imaging of RanBP1
Jurkat cells were plated in a 96-well imaging plate 
(Falcon) and treated with a dilution series of selinexor 
or carrier (DMSO) for 3 hours. After treatment, cells 
were washed with PBS and fixated for 10 minutes in 4% 
PFA. The cells were then washed and remaining PFA 
was inactivated with PBS with 0.1M glycine. Cells were 
permeabilized with PBS containing 0.1% Triton X-100 
for 10 minutes. Subsequently, the cells were washed 
3 times with PBS and then blocked at 37°C for 2 hours 
in 10% Normal Goat Serum. The primary anti-human 
RanBP1 (Ab97659, Abcam) antibody was then added and 
incubated for 1 hour. After primary staining, the cells were 
extensively washed and the secondary antibody, Alexa 
Fluor 488 (A11008, Invitrogen), was incubated for 1 hour 
in the dark. Finally, cells were washed and the nuclei were 
counterstained with DAPI. The plate was imaged using 
the green and blue channels of an ArrayScan XTI High 
Content Reader (ThermoFisher Scientific). Nuclear and 
cytoplasmic compartments were segmented and their 
average pixel intensities were quantitated with the HCS 
Studio software. The obtained nuclear/cytoplasmic ratios 
were analyzed with GraphPad Prism. The experiment was 
repeated two times.
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